Bangladesh pharma market dynamics 2 q 2012

Pharma Market Dynamics
2Q 2012

• Confidentiality Statement
This presentation is solely for the use of IMS clients. No part of it
may be circulated, quoted or reproduced for distribution outside of
the client organization without prior written approval of IMS Health

Bangladesh pharma market: Eskayef is the number
6 company with 4.74% market share
4
18.42
9.52
8.88
5.33 4.93 4.74 4.31 4.12 4.03 3.73
SQUARE INCEPTA BEXIMCO OPSONIN RENATA ESKAYEF A.C.I. ACME ARISTO DRUG
INTL
Share %

Evolution of market share: Top 10 Companies
Recent data indicates good performance of Incepta, Opsonin,
Renata & DI
5
MAT ~ 06/2012 YTD ~ 06/2012 QTR ~ 06/2012
SQUARE 18.42 18.17 17.13
INCEPTA 9.52 9.70 9.78
BEXIMCO 8.88 8.75 8.49
OPSONIN 5.33 5.44 5.47
RENATA 4.93 5.02 5.14
ESKAYEF 4.74 4.74 4.71
A.C.I. 4.31 4.16 4.22
ACME 4.12 4.20 4.07
ARISTO 4.03 4.08 4.07
DRUG INTL 3.73 3.83 3.97

Antibiotic Market: Top 12 Molecules represents 90%
of the 1700 Crore Taka Market
7
17.63
15.79
11.85
10.96
7.68
6.59 6.55
5.47
2.68
1.98 1.81 1.32
Share %

Clindamycin (39% gr) is the highest growing
molecule, followed by Cefuroxime (19% gr)
8
38.80
19.39 18.12 17.76
15.73
6.65
0.65 0.33
-4.11 -4.32 -5.57
-10.29
Growth %

Top Companies in Antibiotic Market: ESK number 8
Renta 3, ACI 5, Sanofi 9
9
22.29
7.47
6.77 6.43 6.16
5.20 5.11 5.09 4.75
3.47
SQUARE INCEPTA RENATA BEXIMCO A.C.I. ACME OPSONIN ESKAYEF SANOFI
AVN
ARISTO
Share %

Antibiotic Market: Incepta & Opsonin have high
growth
10
22.29
7.47
6.77 6.43 6.16
5.20 5.11 5.09 4.75
3.47
6.99
23.97
12.99
8.85
12.67
1.27
17.67
9.73
6.19
4.45
AVN
ARISTO
Share % Growth %

Antibiotic Market: 4 companies in top 10 are loosing
share
11
22.29
7.47 6.77 6.43 6.16
5.20 5.11 5.09 4.75
3.47
-1.11
14.57
4.48
0.63
4.05
-6.47
8.72
1.39
-2.06
-3.34
AVN
ARISTO
Share % Share Growth %

13
Cefuroxime Market: 78% mkt in 3 divisions:
90% in 4 divisions
Dhaka
37%
Chittagong
21%
Rajshahi
20%
Khulna
12%
Barisal
6%
Sylhet
4%
Share %

14
Cefuroxime: market growth is driven by North Bengal
Growth in DHK & CHT is lower than national growth (19%)
37.40
20.77 19.73
12.13
6.04
3.93
16.71
14.20
27.90
19.14
29.97
20.02
Dhaka Chittagong Rajshahi Khulna Barisal Sylhet
Share % Growth %

15
Kilmax: DHK division doing wonderful!
Under-performing in North Bengal & Barisal
5.13
4.36
4.07
4.51
3.56
4.79
MS %

16
Kilmax: DHK having high MS, still growing
Growth improvement opportunity in CHT
5.13 4.36 4.07 4.51 3.56 4.79
37.67
-0.20
47.65
13.52
49.84
9.43
MS % Gr %

17
Furosef VS. Kilmax: High market share gap (13%) in
CHT, low gap in RAJ (7%)
17.19
17.81
11.66
15.53 15.49
17.55
5.13
4.36 4.07 4.51
3.56
4.79
MS %
FUROCEF-RTA KILMAX-ESF

18
Kilbac Vs. Kilmax: High market share gap in CHT
13.05
14.60
10.86 11.20 11.56
10.87
5.13
4.36 4.07 4.51
3.56
4.79
MS %
KILBAC-IAP KILMAX-ESF

19
Kilbac Vs. Kilmax: GAP Analysis
7.92
10.24
6.79 6.69
8.00
6.08
KIlbac VS. Kilmax
GAP

20
Top 5 District: Kilmax MS% high in Mymensingh
Low in Comilla
4.08
4.82
5.50
3.46
4.21
Dhaka Chittagong Mynensingh Comilla Khulna
Kilmax
Share %

21
Top 5 District: Kilmax growth % high in Mymensingh
Negative in Chittagong
9.96
17.12
29.06
20.87 18.91
28.29
-5.29
90.00
39.85 36.93
Dhaka Chittagong Mynensingh Comilla Khulna
Market Growth
Market Kilmax

23
Clindamycin Market: Dhaka and Rajshahi division
dominates the market
Dhaka
39%
Rajshahi
25%
Khulna
14%
Chittagong
14%
Barisal
5%
Sylhet
3%
Share %

24
39.39
24.75
14.36 13.85
4.40 3.25
45.87
53.83
29.83
11.19
41.71
23.91
Dhaka Rajshahi Khulna Chittagong Barisal Sylhet
Share % Growth %
Clindamycin Market: Very high growth for Dhaka,
Rajshahi & Barisal division

25
Incepta VS. Opsonin: Market share GAP is low (7%
GAP) in DHK; High in KHL (18%)
31.34
34.51
39.60
36.96
31.67 30.34
23.96 23.62
21.35
23.80
28.02
25.74
CLINDACIN-IAP CLINDAX-OPI

26
Incepta VS. Opsonin: Clindax growth is better than
Clindacin in all divisions
Major growth difference in Dhaka & Barisal division
11.66
25.44
6.68
-8.12
8.52
-4.89
60.12
37.57
10.61
3.00
40.43
23.78
CLINDACIN-IAP CLINDAX-OPI

Anti-ulcer Market: 3 ESF brands in top 50 ;
QTR figure is encouraging
28
RK~MAT
06/2012
RK~YTD
06/2012
RK~QTR
06/2012
LOSECTIL 2 2 1
PEPTIL-H 21 28 26
ESORAL 29 21 17

30
Omeprazole Market: 60% mkt in 2 divisions:
90% in 4 divisions
Dhaka
34%
Chittagong
24%
Rajshahi
19%
Khulna
12%
Barisal
7%
Sylhet
4%
Share %

31
Losectil in Omeprazole Market: High MS in KHL
Whatever happened in BSL?
19.36 19.21 18.96
22.31
13.94
21.82
Losectil
Share %

32
Losectil in Omeprazole Market: High Growth in KHL
Lower growth in DHK
19.36 19.21 18.96 22.31
13.94
21.82
22.09
37.14 28.15
100.21
40.31
49.52
Losectil
Share % Growth %

33
Seclo Vs. Losectil: market share equally low in all
divisions
Still losing ground in DHK, RAJ, KHL, SYL
19.36 19.21 18.96
22.31
13.94
21.82
28.20
27.06 26.19 26.74
28.10
19.15
MS %
Losectil Seclo

34
Seclo Vs. Losectil: Low gap in KHL
Losectil beats Seclo in SYL!
8.84 7.85 7.23
4.43
14.16
-2.67
Losectil Vs. Seclo
GAP

35
Losectil Share % in 5 Major District: High in CHT
Low in COM, MYM
20.74
23.48
13.92
17.28
19.67
Dhaka Chittagong Comilla Mynensingh Khulna
MS %
LOSECTIL

36
Seclo Vs. Losectil: 5 Major District
20.74
23.48
13.92
17.28
19.67
27.87 27.34 26.83
36.12
24.00
MS %
LOSECTIL SECLO

37
GAP Analysis in District Level:
High gap in MYM & COM
7.13
3.86
12.91
18.84
4.33
GAP
20.74
23.48
13.92
17.28
19.67
27.87 27.34 26.83
36.12
24.00
MS %
LOSECTIL SECLO

39
Esomeprazole: Share is good in DHK & BSL
Lot of works to be done in North Bengal
3.90
3.38
2.94
3.79 3.91
3.41
Esoral
Share %

40
Esomeprazole Market Vs. Esoral Growth
51.67
38.72
79.46
61.60
73.74
55.42
199.39
154.03
218.22 208.34 206.15
161.73
Growth %
Esomeprazole Esoral

41
Maxpro Vs. Esoral: Where is the biggest gap?
24.36 24.81
19.57
21.64
25.43
19.44
3.90 3.38 2.94 3.79 3.91 3.41
MS %
Maxpro Esoral

42
Maxpro Vs. Esoral: High GAP in CHT & BSL
20.46 21.43
16.63
17.85
21.52
16.03
Maxpro Vs. Esoral
GAP

43
Esoral in Top 5 District
Dhaka Chittagong Comilla Khulna Mynensingh
1 MAXPRO RTA
MAXPRO
RTA
MAXPRO
RTA MAXPRO RTA
MAXPRO
RTA
2 SERGEL HT3 SERGEL HT3
SERGEL
HT3 SERGEL HT3
NEXUM
SQA
3 NEXUM SQA
SOMPRAZ
SPI
NEXUM
SQA ESONIX IAP
SERGEL
HT3
4 ESONIX IAP ESONIX IAP
EXIUM
RD7 MAXIMA ACM
EXIUM
RD7
5 EXIUM RD7 NEXUM SQA ESONIX IAP NEXUM SQA ESONIX IAP
6 ESOTID OPI EXIUM RD7
SOMPRAZ
SPI EXIUM RD7
ESORAL
ESF
7 ESORAL ESF ESORAL ESF
ESOTID
OPI PROGESIC IAP
ESOTID
OPI
8 PROGESIC IAP ESOTID OPI NESO ATP SOMPRAZ SPI
PROGUT
PPH
9 NEPTOR SDZ ESOLOK IBN
ESORAL
ESF ESOTID OPI
SOMPRAZ
SPI
10 NESO ATP
PROGUT
PPH
MAXIMA
ACM NESO ATP
OPTON
BXM
?

• The Anti-ulcer Market:
• Promotional Preference

45
CHT: Important for Ranitidine market
24.26 23.71 23.11 22.72
27.96
Omeprazole Pantoprazole Esomeprazole Rabeprazole Ranitidine
Chittagong

46
RAJ: Important for Pantoprazole
18.55
19.88
18.67
17.04
15.76
Rajshahi

47
DHK: Important for Rabeprazole & Ranitidine
34.18
34.77
34.97
36.47
36.11
Dhaka

Bangladesh pharma market dynamics 2 q 2012

Bangladesh pharma market dynamics 2 q 2012

Recomendados

Recomendados

Mais conteúdo relacionado

Semelhante a Bangladesh pharma market dynamics 2 q 2012

Semelhante a Bangladesh pharma market dynamics 2 q 2012 (20)

Mais de Mohammad Masum Chowdhury

Mais de Mohammad Masum Chowdhury (20)

Último

Último (20)

Bangladesh pharma market dynamics 2 q 2012